iOmx refuels with $75M+ on its search for immune checkpoint targets on tumor cells

Nicole DeFeudis

Editor

While a big chunk of oncology research is focused on targeting T-cell regulators to stamp out cancer, iOmx Therapeutics is homing in on immune checkpoint …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

iOmx refuels with $75M+ on its search for immune checkpoint targets on tumor cells

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Ozempic makes list for next round of Medicare drug price negotiations

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

iOmx re­fu­els with $75M+ on its search for im­mune check­point tar­gets on tu­mor cells

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

iOmx refuels with $75M+ on its search for immune checkpoint targets on tumor cells